The question of whether impaired glucose tolerance (IGT) is relevant to cardiovascular disease, is a subset of the more general question of whether glucose levels are related to cardiovascular disease in non-diabetic subjects. The World Health Organization (WHO) criteria for IGT are a plasma glucose level less than 7.8 mmol and a 2-h post glucose load (75 g) value of 7.8-10.9 mmol [1] .
The question of whether impaired glucose tolerance (IGT) is relevant to cardiovascular disease, is a subset of the more general question of whether glucose levels are related to cardiovascular disease in non-diabetic subjects. The World Health Organization (WHO) criteria for IGT are a plasma glucose level less than 7.8 mmol and a 2-h post glucose load (75 g) value of 7.8-10.9 mmol [1] .
Variability of IGT
One problem with IGT is the variability of the oral glucose tolerance test [2] . Subjects who have had IGT at one examination and have been retested within 3 months changed their classification status in up to 75 % of cases [3] . The concept of IGT has been challenged by Yudkin et al. [4] and Stern et al. [5] . In the latter commentary, it was suggested that the category IGT comprised three groups: a) stable persistent IGT; b) subjects who have IGT but are undergoing rapid conversion to non-insulin-dependent diabetes (NIDDM); and c) subjects who actually had normal glucose tolerance (NGT) but on that particular day had high glucose levels and were placed in the IGT category. In low-risk populations for NIDDM such as Europeans, the number of individuals with IGT in the third category would be particularly high. Given the possible problems with the category of IGT, it might seem surprising that IGT is a risk factor for anything, even for diabetes. However, in recent data from six populations (which include both high and low-risk populations for NIDDM), Edelstein et al. [6] have shown that IGT is a consistent predictor of NIDDM.
IGT and cardiovascular factors
Many studies have shown that IGT is associated with increased cardiovascular risk factors. Burchfiel et al. [7] found that subjects with IGT had increased cardiovascular risk factors (decreased high density lipoprotein (HDL) cholesterol and increased triglyceride, blood pressure, and plasma insulin) intermediate between subjects with NGT and NIDDM. In a study of elderly subjects, Mykkä nen et al. [8] found that men and women with IGT had significantly higher total triglycerides, apolipoprotein B (apo B) and lower HDL cholesterol and apo A than men and women with NGT. In addition, women with IGT had significantly higher systolic blood pressure than women with NGT.
Prevalence of coronary heart disease (CHD) in IGT subjects
In elderly Finnish subjects [9] , the prevalence of definite or probable myocardial infarction was not significantly different in either men or women with IGT compared to subjects with NGT. However, the prevalence of angina was higher in men with IGT than in men with NGT. No differences were seen in the prevalence of angina between women with NGT or IGT. In the San Luis Valley Study [10] , the prevalence of overall CHD was increased approximately twofold in both non-Hispanic white men and women with IGT compared to subjects with NGT. However, the prevalence of overall CHD was very similar in Hispanic men and women with IGT and NGT.
Prospective studies of glucose intolerance in nondiabetic subjects (non-WHO criteria)
A number of studies have examined the relation of glucose to CHD prospectively in non-diabetic subjects but did not use WHO standard criteria [1] . Wilson et al. [11] showed that a random glucose level predicted CHD in women (but not in men) in the Framingham study. "Borderline" diabetes also predicted CHD in women but not in men in the Bedford Study [12] . In contrast, the Tecumseh study, a 1 h plasma glucose (after a 100 g glucose load) predicted the development of CHD in men but not in women [13] . In the above three studies adjustment for total cholesterol, cigarette smoking and blood pressure did not abolish the effect of glucose on CHD. However, neither HDL cholesterol nor triglyceride were measured in these studies [11] [12] [13] .
The International Collaborative Group [14] studied the effect of glucose levels 1 h post glucose challenge. In univariate analyses, glucose levels predicted the development of CHD in only three of nine studies and in none of the studies was glucose a significant predictor of CHD in multivariate analyses. In the Whitehall study, glucose levels measured 2 h after a non-standard glucose challenge [15] above the 95th percentile predicted CHD in men [15] . In the Paris Prospective study [16] , 2 h glucose levels did predict the development of CHD in men but this effect was not significant after adjustment for triglyceride and fasting insulin. In the Helsinki Policeman study in men [17] , 1 h and 2 h glucose predicted CHD in univariate but not in multivariate analyses.
Prospective studies of IGT and CHD: WHO criteria
Kuusisto et al. [18] found no differences in the incidence of CHD over a three and a half year follow-up in elderly Finnish subjects (women: NGT (3.1 %) vs IGT (4.4 %); and men: NGT (12.5 %) vs IGT (14.3 %)). However, the number of cases of CHD was small especially in subjects with IGT. In a Japanese study, subjects with IGT had an increased CHD relative risk of 1.9 (95 % Cl = 1.2,3.2) compared to subjects with NGT [19] . This association was essentially unchanged after adjustment for age, gender, systolic blood pressure, body mass index, total and HDL cholesterol, smoking and alcohol.
IGT and atherosclerosis
Few data exist on the association of IGT and direct measures of atherosclerosis such as coronary angiography or B-mode ultrasound of the carotid arteries. In a Japanese study [20] , IGT was significantly associated with intimal medial wall thickness in the carotid arteries.
Summary
Although IGT is clearly associated with increased cardiovascular risk factors, there is currently conflicting data regarding the association of IGT with cardiovascular disease. This is true particularly for stronger study designs, namely prospective studies. This is partly because of the relatively few studies instituted since the WHO IGT criteria were developed [1] but also because there may be uncertainty about whether other risk factors such as blood pressure or dyslipidaemia should be controlled for. If one believes that IGT (that is mildly elevated glucose levels) is responsible for increased cardiovascular risk factors, then multivariate adjustment should not be done. Furthermore, the high variability of the oral glucose tolerance test needs to be taken into account. Lastly, if IGT is a risk factor for CHD, it is not clear that the increased risk of CHD is restricted solely to those IGT subjects who convert to NIDDM.
